192187-33-0

Basic information

• Product Name: 6-(4-chlorobenzoyl)-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one
• CAS NO: 192187-33-0
• Molecular Formula: C₂₃H₁₅Cl₂NO₂
• Molecular Weight: 408.2767
• Mol File: 192187-33-0.mol

Chemical Properties

• Boiling Point: 574.648°C at 760 mmHg
• Flash Point: 301.336°C
• Density: 1.355g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.654
• CAS DataBase Reference: 6-(4-chlorobenzoyl)-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(4-chlorobenzoyl)-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one(192187-33-0)
• EPA Substance Registry System: 6-(4-chlorobenzoyl)-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one(192187-33-0)

Safety Data

• Hazardous Substances Data: 192187-33-0(Hazardous Substances Data)

Upstream product

• 65247-25-8 (2-amino-5-bromo-phenyl)-(3-chloro-phenyl)-methanone 
• 406161-72-6 N-[4-bromo-2-(3-chlorobenzoyl)phenyl]acetamide 
• 280143-23-9 6-bromo-2-chloro-4-(3-chlorophenyl)quinoline 
• 190898-86-3 6-bromo-4-(3-chloro-phenyl)-2-methoxy-quinoline 
• 192187-30-7 4-(3-chlorophenyl)-3,4-dihydro-2(1H)-quinolinone 
• 288391-73-1 5-Bromo-3-(3-chloro-phenyl)-benzo[c]isoxazole 
• 405548-67-6 N-[2-(3-chlorobenzoyl)-4-(4-chlorobenzoyl)phenyl]acetamide 
• 406162-21-8 (4-chlorophenyl)-[4-(3-chlorophenyl)-2-methoxyquinolin-6-yl]methanone 
• 190898-77-2 3-(3-chlorophenyl)-5-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-2,1-benzisoxazole 
• 190898-78-3 [2-amino-5-(4-chlorobenzoyl)phenyl](3-chlorophenyl)-methanone 
• 190898-64-7 2-(4-Chlorophenyl)-2-(4-nitrophenyl)-1,3-dioxolane 
• 74-11-3 para-chlorobenzoic acid 
• 7497-60-1 (4-Chlorophenyl)(4-nitrophenyl)methanone 
• 192187-32-9 R₁₀₁₇₆₃ 

Downstream Products

• 192185-68-5 6-[amino(4-chlorophenyl)-1-methyl-1H-imidazol-5-ylmethyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone 
• 192185-72-1 tipifarnib 
• 406162-93-4 4-(3-chlorophenyl)-6-[(4-chlorophenyl)(4-chloro-3-pyridinyl)hydroxymethyl]-1-methyl-2(1H)-quinolinone 
• 406161-91-9 C₂₆H₂₂Cl₂N₄O₂S 
• 654074-93-8 4-(3-chloro-phenyl)-6-[(4-chloro-phenyl)-(5-mercapto-4-methyl-4H-[1,2,4]triazol-3-yl)-methyl]-1-methyl-1H-quinolin-2-one 
• 654074-97-2 4-(3-chloro-phenyl)-6-[(4-chloro-phenyl)-(1-methyl-1H-tetrazol-5-yl)-methyl]-1-methyl-1H-quinolin-2-one 
• 654074-96-1 4-(3-chloro-phenyl)-6-[(4-chloro-phenyl)-(1H-tetrazol-5-yl)-methyl]-1-methyl-1H-quinolin-2-one 
• 406161-90-8 (4-chloro-phenyl)-[4-(3-chloro-phenyl)-1-methyl-2-oxo-1,2-dihydro-quinolin-6-yl]-acetic acid 
• 192185-51-6 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)-quinolinone 
• 406161-89-5 (4-chloro-phenyl)-[4-(3-chloro-phenyl)-1-methyl-2-oxo-1,2-dihydro-quinolin-6-yl]-acetonitrile 

Relevant articles and documents

Synthesis Routes Towards the Farnesyl Protein Transferase Inhibitor ZARNESTRA

The discovery that post-translational farnesylation of Ras oncoprotein was an essential step in exercising its biological effect led to the design of farnesyl protein transferase inhibitors (FTIs) in order to control growth of tumors bearing Ras mutations. Pre-clinical studies on murine models have confirmed their inhibitory effect on tumor growth and enabled clinical development. R115777 (ZARNESTRA) is currently undergoing clinical evaluation and recent studies have confirmed its antitumor potential and low toxicity. We wish to describe here the chemical synthesis routes that our group have developed to access ZARNESTRA. Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2004.

(Imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation

This invention comprises the use of compounds of formula (I) wherein the dotted line represents an optional bond; X is oxygen or sulfur; R1is hydrogen, C1-12alkyl, Ar1, Ar2C1-6alkyl, quinolinylC1-6alkyul, pyridylC1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, aminoC1-6alkyl, or a radical of formula —Alk1—C(=))—R9or —Alk1—S(O)2—R9; R2, R3and R16each independently are hydrogen, hydroxy, halo, cyano, C1-6alkyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy, aminoC1-6alkyloxy, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, Ar1Ar2C1-6alkyl, Ar2-oxy, Ar2C1-6alkyloxy, hydroxycarbonyl, C1-6alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C2-6alkenyl; R4and R5each independently are hydrogen, halo, Ar1, C1-6-alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, hydroxycarbony, C1-6alkyloxycarbonyl, C1-6alkylS(O)C1-6alkul or C1-6alkylS(O)2C1-6alkyl; R6and R7independenly are hydrogen, halo, cyano, C1-6alkyl, 4,4-dimethyl-oxazolyl, C1-6alkyloxy or Ar2oxyl R8is hydrogen, C1-6alkyl, cyano, hydroxycarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonylC1-6alkyl, cyanoC1-6alkyl, C1-6alkyloxycarbonylC1-6alkyl, carboxyC1-6alkyl, hydroxyC1-6alkyl, aminoC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, imidazolyl, haloC1-6alkyl, C1-6alkyloxyC1-6alkyl, aminocarbonylC1-6alkyl, or a radical of formula —O—R10, —S—R10, —N—R11R12; R17is hydrogen, halo, cyano, C1-6alkyl, C106alkyloxycarbonyl, Ar1; R18is hydrogen, C1-6alkyl, C1-6alkyloxy or halo; R19is hydrogen or C1-6alkyl; for the manufacture of a medicament to inhibit smooth muscle cell proliferation.

Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quionlinone derivatives

PCT No. PCT/EP96/04515 Sec. 371 Date May 26, 1998 Sec. 102(e) Date May 26, 1998 PCT Filed Oct. 16, 1996 PCT Pub. No. WO97/21701 PCT Pub. Date Jun. 19, 1997This invention comprises the novel compounds of formula (I) wherein the dotted line represents an op